Medicare Coverage for Congestive Heart Failure: Hospitalizations, Medications, and Monitoring

Congestive heart failure is the leading cause of hospitalization among Medicare beneficiaries over 65, and managing it involves frequent physician visits, ongoing medication management, monitoring equipment, and often repeated hospitalizations. The Medicare coverage picture for heart failure is comprehensive in some respects and has important gaps in others. Understanding what each part of Medicare covers, and how hospitalization readmission rules and monitoring equipment coverage work, helps patients and caregivers make informed decisions about both care and plan choice.

Bryce's Take

Heart failure is one of the diagnoses where I most actively recommend Medigap over Advantage for the right client. The frequency of cardiology visits, the potential for hospitalizations, the expensive medications, with Medigap Plan G, all of that covered care becomes essentially zero out of pocket. With an Advantage plan, prior auth for cardiac procedures and the accumulated copays from multiple cardiology visits each year can add up significantly. Let me run the total cost comparison for your specific situation.

Inpatient hospitalization for CHF

Acute CHF exacerbations requiring hospitalization are covered under Medicare Part A. The standard inpatient cost-sharing applies: a $1,676 per-benefit-period deductible with no daily coinsurance for the first 60 days, then $419 per day for days 61-90. With Medigap Plan G or N, the daily coinsurance is covered. Repeated hospitalizations are common with CHF, the disease's trajectory often involves periodic decompensation, and each hospitalization after a 60-day gap from the prior discharge starts a new benefit period with a new deductible.

Hospital readmission penalties and what they mean for you

CMS penalizes hospitals financially for excess 30-day readmission rates for CHF, among other conditions. This creates strong institutional incentives for discharge planning and early follow-up care coordination. For patients, this translates to more aggressive post-discharge follow-up programs and care transition support from hospitals. Some hospitals have dedicated heart failure nurse practitioners who contact patients within 48 to 72 hours of discharge and monitor remotely. These programs are in hospitals' financial interest and in your clinical interest.

Outpatient management under Part B

Physician visits for CHF management, laboratory tests including BNP and metabolic panels, echocardiograms, stress tests, and other cardiac imaging are covered under Part B with standard 80/20 cost-sharing. Regular cardiology visits are essential for CHF management; without Medigap, the accumulating 20% coinsurance on multiple cardiology visits and tests per year adds up meaningfully. Medigap's coverage of this coinsurance has particular value for CHF patients who use significant outpatient cardiac care.

Medications under Part D

Heart failure medications including ACE inhibitors, ARBs, ARNIs (sacubitril/valsartan, brand name Entresto), beta-blockers, diuretics, and SGLT2 inhibitors are covered under Part D. Some newer heart failure medications, particularly Entresto, are brand-name drugs that may carry significant Tier 3 or Tier 4 cost-sharing under plans that do not prefer them. Checking your Part D formulary for your specific heart failure medication regimen is important. The $2,000 annual Part D out-of-pocket cap starting in 2025 provides significant protection for CHF patients on expensive medication regimens.

Remote monitoring devices under Part B

Remote patient monitoring for CHF, including pulmonary artery pressure monitors like the CardioMEMS device, may be covered under Part B when Medicare-approved and medically necessary. Implantable devices including implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) devices are covered under Part A when implanted inpatient. External monitoring equipment and telehealth monitoring visits for CHF management have expanded under Medicare's telehealth provisions.

Plan choice implications for CHF patients

For CHF patients, the plan choice between Medicare Advantage and Original Medicare has significant practical implications. Advantage plans may impose prior authorization for cardiology visits, cardiac procedures, and certain medications. Network restrictions in HMO plans may limit access to cardiologists or specialized heart failure centers. For a disease that requires frequent specialist engagement, predictable care access, and sometimes complex interventions, Original Medicare's any-provider coverage and Medigap's zero-cost-sharing for covered services often provide better financial predictability and care access than Advantage plans.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.